Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + FOLFIRI + Bevacizumab for Unresectable Colon Cancer Peritoneal Metastases
NCT05742425Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2023
- Primary completion
- Mar 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in colon cancer, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Mar 2023; status: recruiting.
02
Drugs
serplulimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05742425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05742425.